Median OS was 206 days from start of ITPP infusions, again with no significant differences among tumor types (CCA: 302 days, CRLM: 340 days, HCC: 684 days, PDAC 165 days) or different doses of ITPP. This evidence concerns the gene TPP1 and neoplasm.